Use of systemic anti-infective agents in Iran during 1997-1998

被引:11
作者
Ansari, F [1 ]
机构
[1] Minist Hlthcare & Med Educ, Tehran, Iran
关键词
anti-infective utilization; antibacterial utilization; DUR; Iran;
D O I
10.1007/s002280100351
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Conduction of standardized national drug utilization review to investigate the pattern of systemic anti-infective agent use in Iran. Methods: The wholesale data were used. The Anatomical Therapeutic Chemical (ATC) classification and the defined daily dose (DDD) methodology was employed. Data were presented as DDD/1000 inhabitants/day. Results were compared using national drug statistics of Norway, Sweden, and Denmark. Results: The overall sales of systemic anti-infective agents was 43.5 DDD/1000 inhabitants/day. The parenteral form of drug accounted for 4.20% and broad-spectrum systemic antibacterial agents accounted for 86.2%. The three most commonly used agents, accounting for 74.1% of total sales, were amoxicillin, co-trimoxazole, and ampicillin. Seven kinds of anti-infective agents (17% of total available agents) accounted for 90% of antibacterial use, with dominance of broad-spectrum agents. Comparison showed differences in pattern and intensity of use. The sales of systemic anti-infective agents in general, particularly antibacterials and anti-tuberclotics, were greater in Iran than in three European countries. Broad-spectrum antibacterial agents accounted for a larger proportion of total sales in Iran. Conclusion: The high use of systemic antibacterial agents in general, particularly broad-spectrum agents, suggest the possibility of irrational prescribing, higher prescribed daily doses than DDDs, and a drug wastage. This survey, as a first attempt,. provided an overview of anti-infective use in Iran. Thus, it may serve as a basis for further investigative studies and advanced drug policies.
引用
收藏
页码:547 / 551
页数:5
相关论文
共 9 条
[1]  
ANSARI F, 2001, DRUG WASTAGE UTILIZA
[2]  
BURMAN K, 1998, SEVENSK LAKEMEDELSST
[3]  
COL NF, 1987, REV INFECT DIS S3, V9, P232
[4]  
*DAN MED AG, 1998, MED PROD STAT 1997
[5]  
KUNIN CM, 1990, REV INFECT DIS, V12, P12
[6]  
KUNIN CM, 1987, REV INFECT DIS S3, V9, P270
[7]  
QYDVIN K, 1998, DRUG CONSUMPTION NOR
[8]  
*WHO COLL CTR DRUG, 1998, ATC IND DDDS 1998
[9]  
*WHO COLL CTR DRUG, 1998, GUID ATC CLASS DDD A